OncoMatch/Clinical Trials/NCT04842812

Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors

Is NCT04842812 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 for liver cancer.

Phase 1RecruitingSecond Affiliated Hospital of Guangzhou Medical UniversityNCT04842812Data as of May 2026

Treatment: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 — Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Non-Small Cell Lung Carcinoma

Breast Carcinoma

Colorectal Cancer

Glioblastoma

Tumor Agnostic

Prior therapy

Cannot have received: gene therapy

Lab requirements

Kidney function

adequate kidney function

Liver function

adequate liver function

Cardiac function

adequate heart function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify